Drug intelligence / Profile preview

SAL0137

Development stage: Phase 2
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SAL0137 is an orally bioavailable small molecule drug candidate developed by Shenzhen Salubris Pharmaceuticals for the treatment of dyslipidemia, specifically targeting elevated levels of lipoprotein(a) [Lp(a)]. Elevated Lp(a) is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. SAL0137 is formulated as a tablet and is designed to lower circulating Lp(a) levels, thereby potentially reducing cardiovascular risk. In October 2025, Shenzhen Salubris Pharmaceuticals received acceptance for its clinical trial application (IND) from China's National Medical Products Administration (NMPA), marking the drug's entry into Phase 1 clinical development.

Targets

Lp(a) assembly interface (Lipoprotein(a) assembly interface)

Beyond the preview

Go deeper on SAL0137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL0137.

Explore the full profile